Regeneron, CytomX Set Cancer-Therapy Collaboration
2022年11月17日 - 9:57PM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and CytomX Therapeutics Inc. on
Thursday said they plan to create bispecific cancer therapies under
a collaboration and licensing agreement potentially worth billions
of dollars to CytomX.
Tarrytown, N.Y., biotechnology company Regeneron said it would
make a $30 million upfront payment to CytomX as part of the
collaboration, which would use CytomX's Probody therapeutic
platform and Regeneron's Veloci-Bi bispecific antibody development
platform.
CytomX, a South San Francisco, Calif., clinical-stage
biopharmaceutical company, also is eligible for up to $2 billion in
target-nomination and milestone payments, along with royalties on
product sales.
Shares of CytomX, which closed Wednesday at $1.21, jumped more
than 20%, to $1.47, in premarket trading Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 17, 2022 07:42 ET (12:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 9 2024 まで 10 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 10 2023 まで 10 2024
